iRhythm earnings on deck: Can cardiac monitor maker sustain growth?

iRhythm Technologies is expected to report Q1 revenue of $194.08 million and an adjusted loss of 66 cents per share, reversing from the prior quarter’s 17-cent profit while still implying 22.31% year-over-year revenue growth. Investors are focused on the roughly $15 million sequential revenue decline from Q4, confirmation of full-year 2026 guidance of $870 million to $880 million, and the path back to sustained profitability. Despite a bullish analyst backdrop with 14 of 15 ratings at buy and a $195 mean target, recent target cuts and the stock’s 43% discount to its 52-week high point to some caution.

Analysis

The setup is less about one quarter and more about whether the market is extrapolating a temporary digestion phase into a structural slowdown. A sequential revenue dip after a strong prior print is exactly the kind of cadence that can compress multiples in high-expectation medtech names, because the stock is already priced for a clean slope of adoption; any evidence of lumpiness forces investors to re-underwrite the growth algorithm, not just the next quarter.

The more important second-order issue is margin quality. If the company is still oscillating back to losses while gross margins stay elevated, that usually means the bottleneck is commercial efficiency rather than product demand, which is fixable but slower to prove. In the near term, that shifts the debate to sales productivity, reimbursement friction, and implementation cycles; if those metrics soften, the downside can persist for 1-2 quarters even if the long-term market opportunity remains intact.

Consensus still looks constructive, but the clustering of target cuts tells you the marginal buyer is becoming more sensitive to execution risk. That creates a classic “good story, weak timing” setup: the stock can rerate only if management re-anchors FY26 guidance and shows the sequential decline was calendar noise, while any guide-down likely triggers multiple compression disproportionate to the earnings miss. The broader market tailwind is real, but in growth medtech the TAM rarely protects the stock when operating leverage pauses.

Contrarian angle: the sell-side may be overfocusing on revenue growth and underweighting the possibility that profitability is the cleaner catalyst. If management can show a path to sustained positive EBITDA through mix and efficiency, the stock could recover faster than expected because ownership is likely growth-focused and under-positioned for a margin-led reacceleration. Conversely, if the company needs another quarter of investment-heavy losses, the upside target may stay theoretical for months.

Key Decisions for Investors

• Avoid initiating fresh long exposure ahead of earnings; wait for the print and only buy if FY26 guidance is reaffirmed and the sequential revenue decline is explicitly framed as seasonal. Risk/reward improves materially after confirmation rather than pre-event.
• If already long IRTC, hedge into the event with a short-dated collar or put spread into the next 2-4 weeks. The setup favors an outsized downside reaction if guidance or commentary disappoints, while upside may be capped by already-stretched expectations.
• Post-earnings, consider a tactical long only on a >8-10% drawdown if revenue guidance is held and management emphasizes margin inflection. That would create a better entry point for a 3-6 month mean reversion trade back toward the lowered target band.
• For relative value, pair long a profitable medtech quality name against short IRTC if execution risk persists. The cleaner earnings visibility should outperform if the market continues to penalize unprofitable growth with lumpy cadence.
• If the quarter shows stable top-line but no evidence of operating leverage, use any bounce to reduce exposure rather than add. In that case, the stock likely stays range-bound for 1-2 quarters as investors wait for proof rather than projections.